Cancer Immunity & Immunotherapy Course (organized in partnership with the Society for Immunotherapy of Cancer; separate registration required)

Tuesday, June 21, 2022

7:30 AM – 4:45 PM PT

Location: Nob Hill A/B/C

Speaker(s)

Abul Abbas, MD

University of California, San Francisco

Chair(s)

DP

Daniel Powell

Speaker(s)

MS

Matthew H. Spitzer, Ph.D.

University of California, San Francisco
San Francisco, California, United States
Mark Anderson, MD, PhD

Professor and Director, UCSF Diabetes Center
University of California, San Francisco
San Francisco, California, United States
MH

Michelle Hermiston
Kole Roybal, PhD

Assistant Professor
University of California, San Francisco
San Francisco, California, United States

This course is organized in partnership with the Society for Immunotherapy of Cancer (SITC).

Program Agenda
(all times are listed in Pacific Time)

7:30-8:00 am Continental Breakfast
8:00-8:45 am Basic Principles of Cancer Immunity – Abul Abbas, MD
8:45-9:30 am Vaccination Strategies, Identification of Neoantigens – Lisa Butterfield, PhD
9:30-9:45 am Coffee Break
9:45-10:30 am The Tumor Microenvironment – Matthew Spitzer, PhD
10:30-11:15 am Role of T Cell Exhaustion in Cancer Immunotherapy – John Wherry, MD (virtual lecture)
11:15 am-12:00 pm Next Generation Checkpoint and Combination Therapies – Adil Daud, MD, (virtual lecture)
12:00-12:45 pm Lunch
12:45-1:30 pm Immune-Related Toxicity: Mechanisms and Management – Mark Anderson, MD, PhD
1:30-2:15 pm CAR-T Cell Therapy: Principles and Current Practices – Michelle Hermiston, MD, PhD
2:15-3:00 pm CAR-T Cell Therapy: Next Generation CARs, Toxicities, Challenges and Prospects – Michelle Hermiston, MD, PhD
3:00-3:15 pm Coffee Break
3:15-4:00 pm Adoptive Cell Therapies: More than CAR-T – Daniel Powell, PhD (virtual lecture)
4:00-4:45 pm Next Generation Strategies – Kole Roybal, PhD
4:45 pm Adjourn

Learning Objectives:

Describe mechanisms of the immune response against cancer cells and how these responses are regulated during cancer development and progression.
Describe the principles underlying chimeric antigen receptor transduced T cells (CAR-T cells) and T cell receptor (TCR)-transduced T cells and their efficacy in the treatment of leukemias and other cancers.
Appreciate the potential opportunities and limitations of utilizing CAR-T cells for treating solid tumors and understand the development of second-generation CARs.
Understand the biology of immune checkpoint pathways and checkpoint blockade therapy for solid tumors, the development of biomarkers to predict therapeutic responses, and the potential for combination therapies.
Describe the unique adverse event profile associated with immune checkpoint blockade and CAR-T cell therapy, and clinical strategies for managing those immune-related toxicities.
Understand the potential of emerging strategies for cancer immunotherapy.